The bromodomain and extra-C-terminal domain (BET) protein family is a class of epigenetic readers that recognize acetyl-lysine residues of histones, and their targeting with small molecules is a novel therapeutic approach [[1]]. Cell cycle and apoptosis induction were evaluated in a subset of cell lines, including two resistant models (NALM1, K562) after 48-h treatments with 500 nM OTX015 (Figure 1(A)). Similarly, OTX015 significantly down-regulated I MTHFD1L i and I BCL2 i in all leukemic cell lines after 4 or 24 h of treatment, in a similar manner as I MYC i , although the effect on I BCL2 i appeared reversible in three nonresistant cell lines (Figure S2). We then evaluated the downstream effects of OTX015 (500 nM) combined with azacitidine (3 µM) or panobinostat (20 nM) in sensitive and resistant OTX015 cell lines. [Extracted from the article]